

April 30, 2008



Dutton Associates Announces Investment Opinion: Pressure BioSciences Strong Speculative Buy Rating In Update Coverage By Dutton Associates

ROSEVILLE, Calif.--(BUSINESS WIRE)--

Dutton Associates updates its coverage of Pressure BioSciences (Nasdaq: PBIO) maintaining a Strong Speculative Buy rating and a 12-month target price of \$8. The 15-page report by Dutton senior analyst Denise T. Resnik, M.S. is available at www.jmdutton.com as well as from First Call, Bloomberg Professional, Zacks, Reuters, Knobias, and other leading financial portals.

Pressure BioSciences has developed a unique and superior technology for the preparation of biological laboratory samples and is in the early stages of commercialization of its product platform. While the rollout of this technology and the Company's products has been somewhat disappointing (as reflected by the past two quarters' revenues), we believe that, as the sales force is now in place, sales should ramp up in coming quarters, and investors will increasingly recognize the value inherent to this technology. The Company continues to drive its installed base of Pressure Cycling Technology (PCT) Sample Preparation Systems to enable it to realize increases in its recurring revenue streams from PULSE Tubes, ProteoSolveLRS kits, and extended service contracts. Toward this end, the Company has increased the number of leads in the U.S. by over 2,000 and is also ahead of schedule in building its international distribution network with distribution agreements with three partners covering France, Switzerland, Belgium, Japan, and Korea. We expect that the shares will begin to reflect the substantial profits that we believe the Company can generate beginning in 2011. We are reiterating our rating of the Company as a Strong Speculative Buy; however, reflecting the current market environment, we are reducing our 12-month price target from \$10.00 to \$8.00 per share.

About Dutton Associates

Dutton Associates is one of the largest independent investment research firms in the U.S. Its 30 senior analysts are primarily CFAs and have expertise in many industries. Dutton & Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.

The cost of enrollment in our one-year continuing research program is US \$35,000 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received \$32,000 from the Company for 4 Research Reports with coverage commencing on 9/12/07. The Firm does not accept any equity compensation. Our principals

and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.

Source: Pressure BioSciences